The first incision-free endoscopic treatment for severe obesity and metabolic disease, ForePass ® aims to replicate Roux-en-Y Gastric Bypass, RYGB.
Metabolic surgery can achieve substantial and durable weight loss and improvements in type 2 diabetes and other obesity-related conditions. However, it is invasive and carries perioperative and longer-term risks, limiting its suitability and acceptance for many patients.
Existing endoscopic and device-based therapies can offer less-invasive treatment options, but generally produce more modest weight loss than metabolic surgery. This leaves a significant treatment gap for patients requiring substantial weight loss and metabolic improvement.
GLP-1–based therapies have transformed obesity treatment and can produce substantial weight loss and metabolic benefits. However, response varies between patients, treatment is generally chronic, and rapid weight regain can occur following discontinuation. A significant need therefore remains for patients who do not achieve or maintain sufficient benefit with pharmacotherapy.
ForePass® is fully endoscopic device designed to reproduce key mechanisms of metabolic surgery without surgical resection or anastomosis. Preclinical studies have demonstrated encouraging effects on weight and metabolic parameters, supporting its continued development toward clinical evaluation.
Keyron’s patented ForePass® device is designed to target key mechanisms underlying insulin resistance and obesity.
ForePass® is a technology platform designed to replicate key mechanisms of Roux-en-Y gastric bypass and other metabolic surgery procedures, without requiring incisions in the abdomen or digestive tract.
The final device may differ in size and characteristics to that shown in this video.
Our large-animal data were published in Gut, the official journal of the British Society of Gastroenterology and one of the leading journals in gastroenterology and hepatology.
Preclinical studies have demonstrated substantial effects on weight and metabolic outcomes. In animal studies, ForePass® showed the following changes from baseline compared with endoscopic controls:
Purpose-Built For 100% Reversibility
ForePass ® reduced body weight, glycemia, insulin resistance and liver fat deposition to levels comparable to Roux-en-Y gastric bypass in this animal study.
It produced metabolic reversal with weight and metabolic outcomes not statistically different from Roux-en-Y gastric bypass.
Note: ForePass ® was previously named Sleeveballoon.
ForePass ® is an extremely promising technology which may allow us to deliver the same benefits of metabolic surgery but without the complications from a surgical procedure
The rodent data obtained with ForePass shows that the device may reach the same unmatched efficacy of metabolic surgery.
ForePass could allow many more people to access the efficacy that metabolic surgery is known for. Its elegant anchoring system could ensure the required safety that so many other devices in the space have not been able to achieve
